Andrew Wei

Personal profile

Biography

Dr Andrew Wei is a Victorian Cancer Agency Research Fellow and Haematologist at the Alfred Hospital. Andrew conducts clinical and translational AML research through dual appointments at the Alfred Hospital and Monash University.

After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, he joined the Alfred Hospital in 2008 to develop the AML research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator. His doctoral research studies contributed to discoveries elucidating the functional interaction between Bcl-2 family members (Molecular Cell 2005;17(3):393-403), the role of Mcl-1 in cancer susceptibility to ABT-737 (Cancer Cell. 2006;10(5):389-99) and the pro-survival function of the EBV Bcl-2 homologue BHRF-1 (PLoS Pathogens 2010;6[12]).

Dr Wei is an executive member of the ALLG Scientific Advisory Committee, a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia and Head of Leukaemia Research at the Alfred hospital. He sits on the International Steering Committee for Celgene providing expert advice on AML. To enhance translational research, Dr Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2009 2026

17 Finished
22 Active

A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy.

Wei, A. & Kennedy, N.

22/10/19 → 31/12/24

Project: Research

A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia.

Wei, A., Tiong, I. S., Reynolds, J. & Kennedy, N.

22/09/19 → 31/12/24

Project: Research

The International AML Platform Consortium (IAPC) trial.

Wei, A. & Kennedy, N.

5/09/19 → 31/12/24

Project: Research

A Phase Ib/II Study, Evaluating the Safety and Efficacy of Idasanutlin in Combination with Cytarabine and Daunorubicin in Patients Newly Diagnosed with Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission.

Wei, A. & Kennedy, N.

17/07/19 → 31/12/26

Project: Research

A Phase 1, Dose Escalation Study of Flotetuzumab, a CD123 x CD3 DART Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Wei, A. & Kennedy, N.

9/07/19 → 31/12/24

Project: Research

Research Output 2001 2019

69 Article
17 Letter
5 Comment / Debate
3 Review Article
2 More
- 1 Abstract
- 1 Poster

17 Citations (Scopus)

Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T. C., Tiong, I. S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F. & 7 others, Segal, D., Huang, D., Roberts, A. W., Maragno, A. L., Lessene, G., Geneste, O. & Wei, A. H., 1 Apr 2019, In : Leukemia. 33, a, p. 905-917 13 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

File

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (Blood Cancer Journal, (2018), 8, 8, (68), 10.1038/s41408-018-0103-6)

Marquis, M., Beaubois, C., Lavallée, V. P., Abrahamowicz, M., Danieli, C., Lemieux, S., Ahmad, I., Wei, A., Ting, S. B., Fleming, S., Schwarer, A., Grimwade, D., Grey, W., Hills, R. K., Vyas, P., Russell, N., Sauvageau, G. & Hébert, J., 1 Mar 2019, In : Blood Cancer Journal. 9, 3, 1 p., 28.

Research output: Contribution to journal › Comment / Debate › Other › peer-review

Open Access

8 Citations (Scopus)

Genomic subtyping and therapeutic targeting of acute erythroleukemia

Iacobucci, I., Wen, J., Meggendorfer, M., Choi, J. K., Shi, L., Pounds, S. B., Carmichael, C. L., Masih, K. E., Morris, S. M., Lindsley, R. C., Janke, L. J., Alexander, T. B., Song, G., Qu, C., Li, Y., Payne-Turner, D., Tomizawa, D., Kiyokawa, N., Valentine, M., Valentine, V. & 28 others, Basso, G., Locatelli, F., Enemark, E. J., Kham, S. K. Y., Yeoh, A. E. J., Ma, X., Zhou, X., Sioson, E., Rusch, M., Ries, R. E., Stieglitz, E., Hunger, S. P., Wei, A. H., To, L. B., Lewis, I. D., D’Andrea, R. J., Kile, B. T., Brown, A. L., Scott, H. S., Hahn, C. N., Marlton, P., Pei, D., Cheng, C., Loh, M. L., Ebert, B. L., Meshinchi, S., Haferlach, T. & Mullighan, C. G., Apr 2019, In : Nature Genetics. 51, 4, p. 694-704 11 p.

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia

McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., Erlichster, M., Witkowski, M. T., Liu, G. J., Chopin, M., Dakic, A., Simankowicz, E., Pomilio, G., Vu, T., Krsmanovic, P., Su, S. & 21 others, Tian, L., Baldwin, T. M., Zalcenstein, D. A., DiRago, L., Wang, S., Metcalf, D., Johnstone, R. W., Croker, B. A., Lancaster, G. I., Murphy, A. J., Naik, S. H., Nutt, S. L., Pospisil, V., Schroeder, T., Wall, M., Dawson, M. A., Wei, A. H., de Thé, H., Ritchie, M. E., Zuber, J. & Dickins, R. A., 1 Aug 2019, In : Cell Stem Cell. 25, 2, p. 258-272.e9 24 p.

Research output: Contribution to journal › Article › Research › peer-review

48 Citations (Scopus)

AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies

Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., Cardozo, M., Houze, J., Li, Y., Lucas, B., Paras, N. A., Wang, X., Taygerly, J. P., Vimolratana, M., Zancanella, M., Zhu, L. & 18 others, Cajulis, E., Osgood, T., Sun, J., Damon, L., Egan, R. K., Greninger, P., McClanaghan, J. D., Gong, J., Moujalled, D., Pomilio, G., Beltran, P., Benes, C. H., Roberts, A. W., Huang, D. C., Wei, A., Canon, J., Coxon, A. & Hughes, P. E., 1 Dec 2018, In : Cancer Discovery. 8, 12, p. 1582-1597 16 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

File

Prizes

2003: Albert Baikie Award, Best Oral Abstract Presentation, Haematology Society of Australia

Andrew Wei (Recipient), 2004

Prize: Prize (including medals and awards)

2003: Young Investigator Award, Best Oral Abstract Presentation, Annual Scientific Meeting, Hobart

Andrew Wei (Recipient), 2003

Prize: Prize (including medals and awards)

2004: New Investigator Award, Best Oral Abstract, Annual Scientific Meeting, Canberra

Andrew Wei (Recipient), 2004

Prize: Prize (including medals and awards)

Activities 2012 2012

8 Membership of an advisory panel/policy group/ board